Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
MedImmune LLC
A Randomized, Double-blind, Placebo-controlled, Parallel-designed Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects of MEDI5884 in Participants with Stable Coronary Heart Disease.
Age
45–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Diagnosis of stable coronary heart disease prior to screening
Currently receiving high intensity statin(s)
You may not be if
Unstable cardiovascular conditions
Any planned arterial revascularizations
Fasting Laboratory values at screening: Triglycerides \> 500 mg/dl, Low Density Lipoprotein-Cholesterol \> 100 mg/dL
Any disease or condition or laboratory value that would place the participant at an unacceptable risk.
